Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
Ab183450-100μg
|
100μg |
10
|
$109.90
|
|
|
Ab183450-1mg
|
1mg |
4
|
$519.90
|
|
|
Ab183450-5mg
|
5mg |
1
|
$1,299.90
|
|
|
Ab183450-10mg
|
10mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$2,079.90
|
|
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Erlizumab (anti-CD18) - Primary antibody, specific to ITGB2, Human IgG1, NEGATIVE MODULATOR of Integrin beta-2 negative modulator |
|---|---|
| Synonyms | 95 subunit beta antibody | Beta 2 (antigen CD18 (p95) antibody | CD 18 antibody | CD18 antibody | Cell surface adhesion glycoprotein LFA 1/CR3/P150,959 beta subunit precursor) antibody | Cell surface adhesion glycoproteins LFA 1/CR3/p150,95 subunit beta a |
| Specifications & Purity | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA |
| Host species | Human |
| Specificity | ITGB2 |
| Conjugation | Unconjugated |
| Grade | Animal Free, Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Action Type | NEGATIVE MODULATOR |
| Mechanism of action | NEGATIVE MODULATOR of Integrin beta-2 negative modulator |
| Product Description |
Erlizumab (anti-CD18) is a humanized monoclonal antibody targeted against Integrin beta-2 and used as a therapy for hemorrhagic shock. |
| Isotype | Human IgG1 |
|---|---|
| Light Chain Type | kappa |
| SDS-PAGE | 145 kDa |
| Purification Method | Protein A purified |
| Shape | Liquid |
| Concentration | See COA |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle. |
| CAS | 211323-03-4 |
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Erlizumab (anti-CD18) (Ab183450) - Flow Cytometry
Flow Cytometry analysis of Jurkat cells labelling CD18 (red) with Erlizumab (anti-CD18) (Ab183450). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Erlizumab (anti-CD18) (Ab183450) - SEC
The purity of Erlizumab (anti-CD18) (Ab183450) is more than 95% verified by HPLC.
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
| Certificate of Analysis | Jul 11, 2024 | Ab183450 | |
| Certificate of Analysis | Jul 11, 2024 | Ab183450 | |
| Certificate of Analysis | Jul 11, 2024 | Ab183450 |
Starting at $29.90